Alnylam Receives European Commission Approval for AMVUTTRA ® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA ® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis (hATTR) in adults.
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Share
'Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved patient population,' said Pushkal Garg, M.D., Chief Medical Officer at Alnylam. 'AMVUTTRA is supported by a well-established efficacy and safety profile, with over 6,000 patient-years of global experience in the treatment of hATTR with polyneuropathy. By delivering rapid and sustained knockdown of TTR through convenient, quarterly dosing, it offers a clinically differentiated approach with the potential to transform outcomes for patients living with this debilitating and potentially fatal disease. We now look forward to securing access to AMVUTTRA for eligible patients across the EU as quickly as possible.'
The EC decision is based on positive results from the pivotal HELIOS-B Phase 3 study – a randomized, double-blind, placebo-controlled, multicenter, global trial that enrolled a diverse group of patients reflective of the contemporary ATTR-CM population, including those receiving substantial concurrent use of available standard-of-care therapies such as tafamidis and SGLT2 inhibitors. AMVUTTRA met all 10 pre-specified primary and secondary endpoints across both the overall and monotherapy populations. These included statistically significant reductions in all-cause mortality and recurrent cardiovascular events, as well as significant improvements in functional capacity (6-minute walk test), health status and quality of life (Kansas City Cardiomyopathy Questionnaire), and heart failure symptoms and severity (NYHA class). In the overall population, AMVUTTRA achieved a 28% reduction in the primary composite of all-cause mortality and recurrent cardiovascular events as compared to placebo. Mortality in this population was significantly reduced by 36% through 42 months in a pre-specified secondary endpoint analysis which included up to 36 months of the double-blind period plus six months of open-label extension. In HELIOS-B, rates of adverse events (AEs), serious AEs, severe AEs and AEs leading to study drug discontinuation were similar between the AMVUTTRA and placebo arms. Adverse drug reactions of AMVUTTRA include injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. Detailed results from the HELIOS-B study were published in The New England Journal of Medicine. 1
'The HELIOS-B findings provide compelling evidence to support the use of vutrisiran as a first-line treatment option for patients with ATTR-CM,' said Marianna Fontana, M.D., Ph.D., HELIOS-B investigator, Professor of Cardiology, University College London, National Amyloidosis Center, Royal Free Hospital, London. 'As a physician, it is a privilege to see the true impact on patients in the clinic. The trial enrolled a broad population reflective of real-world clinical practice, and that's what makes the results so meaningful. This is a milestone for patients, who now have a new treatment option that has the potential to significantly improve outcomes of this disease.'
ATTR-CM is caused by the deposition of misfolded TTR fibrils, which drive progressive and irreversible cardiovascular damage and premature death. AMVUTTRA is an RNAi therapeutic that works upstream by delivering sustained knockdown of disease-causing TTR at its source. In the EU, it is administered as a subcutaneous injection once every three months, either by a healthcare professional, or self-administered by patients or their caregivers, offering flexibility in treatment delivery.
'Amyloidosis is a serious and progressive disease that significantly impacts not only patients' physical health, but also their quality of life and independence. I am thrilled by the news of a new therapy for people in the EU living with ATTR-CM who often face delayed diagnosis. Having a new treatment option available marks a welcome development for the amyloidosis community,' said Giovanni d'Alessio, President of the Amyloidosis Alliance.
In May 2025, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the maintenance of the EU Orphan Designation for AMVUTTRA in ATTR amyloidosis.
AMVUTTRA was approved in March 2025 by the U.S. Food and Drug Administration (FDA) and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of the cardiomyopathy of wild-type or hereditary ATTR amyloidosis in adults. Alnylam continues to pursue additional global submissions to bring vutrisiran to patients worldwide.
Indications
In the EU, AMVUTTRA ® (vutrisiran) is indicated for the treatment of:
hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN).
wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Important Safety Information
Reduced Serum Vitamin A Levels and Recommended Supplementation
Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).
Adverse Reactions
Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase.
For additional information about vutrisiran, please see the full Summary of Product Characteristics.
About AMVUTTRA ® (vutrisiran)
AMVUTTRA ® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of variant and wild‑type transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection, vutrisiran is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. It is also approved in the U.S. and Brazil for the treatment of wild-type or hereditary ATTR amyloidosis in adult patients with cardiomyopathy (ATTR-CM). In the EU, AMVUTTRA is administered once every three months, either by a healthcare professional or through self-administration by patients or their caregivers.
About ATTR
Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant and impacts an estimated 200,000-300,000 people worldwide. 2-5
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. 6 Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. 7 By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made. 6 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its ' Alnylam P 5 x25 ' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
Alnylam Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam's expectations regarding the safety and efficacy of AMVUTTRA for the treatment of ATTR-CM; the potential for AMVUTTRA to be used as a first-line treatment for ATTR-CM; the potential for AMVUTTRA to address the underserved ATTR-CM patient population and to improve outcomes for ATTR-CM patients; and Alnylam's ability to secure access to AMVUTTRA for eligible patients across the EU and the timing of such access should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its ' Alnylam P 5 x25 ' strategy; Alnylam's ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates; actions or advice of regulatory agencies and Alnylam's ability to obtain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; and any delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; as well as those risks more fully discussed in the 'Risk Factors' filed with Alnylam's 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

21 minutes ago

• Yahoo

Could the "Next Nvidia Stock" Actually Be... Nvidia Stock?

There seems at least a solid probability that Nvidia stock still has not just good or even great but amazing growth potential left. Year-over-year earnings growth solidly in the double-digit percentages and a reasonable stock valuation should be all that's needed to keep Nvidia investors very happy. 10 stocks we like better than Nvidia › Many articles have been written over the last year or so about "the next Nvidia (NASDAQ: NVDA) stock," which refers to a stock that has the potential to post incredibly strong gains over at least the medium term, just like the artificial intelligence (AI) chip leader has done. With the risk of sounding like I've lost my mind, I think there's a good case to be made that "the next Nvidia stock" could actually be Nvidia stock. In other words, there seems at least a solid probability that Nvidia stock still has not just good or even great but amazing growth potential left. Think of it as "Nvidia the superstar stock 2.0." I say "at the risk of sounding like I've lost my mind" because I understand the law of large numbers strongly works against my thesis. This "law" basically means that the larger a company becomes, the more difficult it becomes to continue to grow revenue and earnings at a strong pace on a year-over-year percentage basis. And year-over-year earnings (and cash flow) growth is what largely powers stock prices higher. Nvidia is massive. It has a market cap of $3.55 trillion, as of June 18, making it the world's second most valuable publicly traded company, trailing Microsoft by just a sliver. Moreover, Nvidia management expects the company to generate revenue of $45 billion in its fiscal second quarter, which equates to an annual revenue run rate of $180 billion. To be clear -- I think it's highly unlikely that Nvidia will ever again be able to pump out a long consecutive string of year-over-year quarterly earnings growth in the very high double-digit to triple-digit percentages. But I don't think it has to do that in order to deliver stellar returns to investors for some time. Year-over-year earnings growth solidly in the double-digits plus a reasonable stock valuation should be all that's needed to keep investors very happy. What makes me have confidence in the "reasonable valuation" bit? Currently, Nvidia stock's valuation is reasonable by just about every measure, but that has not always been true. (For reference, it's trading at 25.4 times Wall Street's projected forward earnings per share, or EPS, as of June 18. That's an attractive valuation for a company that analysts expect will grow EPS at an average annual rate of 30% over the next five years.) The main reason I think the valuation will likely remain relatively reasonable (at least much of the time) for a while circles back to that law of large numbers. Wall Street analysts and many investors are well aware of this phenomenon, and I think most folks in both those groups will tend to continue to significantly underestimate Nvidia's future earnings growth potential due to thoughts like these: An investor and analyst thought: It's so massive, there's no way it can keep growing earnings much. An investor thought: After its massive run-up, I've missed my chance to buy Nvidia stock. (How many of us thought that about, say, Amazon many years ago, only to be proven wrong?) Consistent beliefs like these will help keep Nvidia stock's valuation reasonable in part because Wall Street analysts are going to tend to be too conservative in their estimates, in my view. Moreover, some investors will probably feel that Wall Street is being too liberal in their estimates because they themselves feel cautious given Nvidia's humongous size. Yes, this caution among many investors would likely slow down Nvidia stock's rise, but that's better than the stock frequently shooting up to unsustainable levels, only to plunge back down to Earth, in my opinion. This topic could be several articles, so here's just a brief list. 1. The company's now-annual cadence of launching new graphics processing unit (GPU) architectures for its products for its AI-accelerated data center, gaming, and other market platforms. Blackwell is its current architecture. 2. The approach of the widespread legalization of autonomous vehicles. Nvidia's GPUs will be the "brains" inside many of these vehicles. 3. The approach of the era of humanoid robots. Nvidia's GPUs will be the "brains" inside many of these robots. 4. The company will stay ahead of the innovation pack by entering emerging new technologies via organic growth and acquisitions. An example here is quantum computing, in which I think Nvidia will be increasingly involved. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Beth McKenna has positions in Nvidia. The Motley Fool has positions in and recommends Amazon, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Could the "Next Nvidia Stock" Actually Be... Nvidia Stock? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

22 minutes ago

• Yahoo

Is Textron Stock Underperforming the Nasdaq?

Valued at a market cap of $13.8 billion, Textron Inc. (TXT) is a multi-industry company that leverages its global network of aircraft, defense, industrial, and finance businesses to provide customers with various solutions and services. The Providence, Rhode Island-located company operates in six segments: Textron Aviation, Bell, Textron Systems, Industrial, Textron eAviation, and Finance. Companies valued at $10 billion or more are generally classified as 'large-cap' stocks, and Textron fits this description perfectly. The company owns well-known brands like Bell Helicopters, Cessna, and Beechcraft aircraft, and Textron Systems. Dear Tesla Stock Fans, Mark Your Calendars for June 30 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio Nvidia Is Quickly Approaching a New Record High. Is It Too Late to Buy NVDA Stock? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Textron stock has declined 19% from its 52-week high of $94.57. TXT stock has risen 3.2% over the past three months, lagging behind the broader Nasdaq Composite ($NASX), which increased 11.7% during the same period. In the longer term, TXT stock has marginally increased on a YTD basis, underperforming NASX's 1.2% return. Additionally, shares of Textron have dropped 10.9% over the past 52 weeks, compared to NASX's 9.4% gain over the same period. The stock has been trading below its 200-day moving average since late October last year. However, it has climbed above its 50-day moving average since May. Textron stock rose 2.6% following the release of its strong Q1 2025 results on Apr. 24. The company reported revenue of $3.3 billion, up 5.5% from the same quarter last year, surpassing the consensus estimate. Growth was primarily led by the Bell segment, which jumped 35.2%, driven by robust performance in both military and commercial product lines. Meanwhile, its adjusted EPS came in at $1.28, up 6.7% year-over-year, exceeding analysts' expectations. TXT reaffirmed its full-year 2025 adjusted EPS guidance of $6 to $6.20. Compared to its rival, L3Harris Technologies, Inc. (LHX) has outperformed TXT stock. LHX stock has increased 11.9% over the past 52 weeks and 18.3% on a YTD basis. Despite TXT's underperformance relative to the Nasdaq, analysts are moderately optimistic about its prospects. Among the 14 analysts covering the stock, there is a consensus rating of 'Moderate Buy,' and it is currently trading below the mean price target of $86.71. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Yahoo

26 minutes ago

• Yahoo

Tesla's $56K India Gamble: Will the Model Y Sell in a Price-Sensitive Market?

Tesla (NASDAQ:TSLA) is finally hitting the accelerator in India. After years of back-and-forth, the EV giant is opening its first showroom in Mumbai this July, followed by another in New Delhi. It's starting with the Model Yshipped straight from its Shanghai plantmarking the company's first official sales push into the world's third-largest car market. Internal documents and people familiar with the matter confirm that Tesla has also brought in Supercharger hardware, car accessories, and parts from the US, China, and the Netherlandslaying the groundwork for a broader rollout. This move follows Elon Musk's February meeting with Indian Prime Minister Narendra Modi and could signal the start of a long-term India strategy. But it won't be an easy ride. Each Model Y imported was declared at just under $32,000, but racked up over $25,000 in import duties due to India's 70% tariff on fully-built EVs. Final sticker price? North of $56,000 before tax and insurancenearly 50% more than the U.S. price post-incentives. For a market where EVs still make up just 5% of new car sales and luxury vehicles are under 2%, Tesla will need more than brand power to spark volume. Still, the company is quietly building momentum. It's securing warehouse space in Karnataka and Gurugram, boosting hiring across charging, retail, and policy teams, and sending execs from abroad to oversee showroom setup in luxury districts. The early signs point to a premium positioning play aimed at affluent Indian buyers. Whether that strategy holdsor pivotswill depend on how fast Tesla can shift from imports to local production. For now, it's a high-stakes, high-margin experiment in one of the world's fastest-growing auto markets. This article first appeared on GuruFocus.